Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Clinical trials of HIV vaccines.

Graham BS.

Annu Rev Med. 2002;53:207-21. Review.

PMID:
11818471
2.

Development of prophylactic AIDS vaccines: the current state of affairs.

Hanke T.

Curr Opin Mol Ther. 2003 Feb;5(1):25-32. Review.

PMID:
12669467
3.

Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.

Nehete PN, Chitta S, Hossain MM, Hill L, Bernacky BJ, Baze W, Arlinghaus RB, Sastry KJ.

Vaccine. 2001 Dec 12;20(5-6):813-25.

PMID:
11738745
4.

AIDS vaccine: present status and future challenges.

Nigam PK, Kerketta M.

Indian J Dermatol Venereol Leprol. 2006 Jan-Feb;72(1):8-18. Review.

5.

HIV vaccines in infants and children.

Lambert JS.

Paediatr Drugs. 2005;7(5):267-76. Review.

PMID:
16220994
6.

Challenges in the search for an HIV vaccine.

Lemckert AA, Goudsmit J, Barouch DH.

Eur J Epidemiol. 2004;19(6):513-6. Review.

PMID:
15330122
7.

Development of prophylactic vaccines against HIV-1.

Schiffner T, Sattentau QJ, Dorrell L.

Retrovirology. 2013 Jul 17;10:72. doi: 10.1186/1742-4690-10-72. Review.

8.

Vaccines and vaccine strategies against HIV.

Stratov I, DeRose R, Purcell DF, Kent SJ.

Curr Drug Targets. 2004 Jan;5(1):71-88. Review.

PMID:
14738219
9.

Novel directions in HIV-1 vaccines revealed from clinical trials.

Excler JL, Tomaras GD, Russell ND.

Curr Opin HIV AIDS. 2013 Sep;8(5):421-31. doi: 10.1097/COH.0b013e3283632c26. Review.

PMID:
23743791
10.
11.

[HIV/AIDS vaccines: heading for new vaccine approaches?].

Girard MP.

Bull Soc Pathol Exot. 2008 Jun;101(3):220-6. French.

PMID:
18681215
12.

Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.

Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, Keefer M, Schwartz D, Gorse G.

J Infect Dis. 1998 Feb;177(2):301-9.

13.
14.

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.

Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ.

AIDS. 1998 Dec 24;12(18):2407-15.

PMID:
9875578
15.

Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.

Chakrabarti BK, Ling X, Yang ZY, Montefiori DC, Panet A, Kong WP, Welcher B, Louder MK, Mascola JR, Nabel GJ.

Vaccine. 2005 May 16;23(26):3434-45.

PMID:
15837367
16.

Progress in the development of an HIV-1 vaccine.

Letvin NL.

Science. 1998 Jun 19;280(5371):1875-80. Review.

PMID:
9632379
17.

Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.

Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S, Okuda K, Zolla-Pazner S, Yamazaki S, Yamamoto N, Honda M.

J Virol. 2005 Feb;79(3):1452-62.

18.

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.

Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, Fast PE.

Ann Intern Med. 1996 Aug 15;125(4):270-9.

PMID:
8678389
19.

[Development of an AIDS vaccine: status report].

Girard MP.

Med Trop (Mars). 2007 Aug;67(4):340-6. French.

PMID:
17926791
20.

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

Srivastava IK, Ulmer JB, Barnett SW.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S33-52. Review.

PMID:
15285704
Items per page

Supplemental Content

Support Center